[登录] [免费注册]
试剂仪器网
发布求购
位置：首页 > 产品库 > PTP1B-IN-9
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
PTP1B-IN-9
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
PTP1B-IN-9图片
CAS NO:145888-79-5
包装与价格：
包装价格(元)
10mM (in 1mL DMSO)电议
10mg电议
50mg电议
100mg电议

产品介绍
PTP1B-IN-9 是一种泛素-蛋白酶体系统 (UPS)-应激源。 PTP1B-IN-9 抑制泛素介导的 20S 蛋白酶体催化活性上游的蛋白质降解。 PTP1B-IN-9 触发泛素-蛋白酶体系统 (UPS)-应激反应，而不影响 20S 蛋白酶体催化活性。抗癌活性。
Cas No.145888-79-5
Canonical SMILESO=C(/C(CNC/1)=C/C2=CC=C(Cl)C(Cl)=C2)C1=C\C3=CC(Cl)=C(C=C3)Cl
分子式C19H13Cl4NO
分子量413.12
溶解度DMSO: 5 mg/mL (12.10 mM)
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

PTP1B-IN-9 is a ubiquitin-proteasome system (UPS)-stressor. PTP1B-IN-9 inhibits ubiquitin-mediated protein degradation upstream of the 20S proteasomal catalytic activites. PTP1B-IN-9 triggers a ubiquitin-proteasome-system (UPS)-stress response without affecting 20S proteasome catalytic activities. Anticancer activity[1].

PTP1B-IN-9 (0-30 µM; 48 hours) treatment produces a dose dependent reduction in the viability of HPV16-positive SiHa and Caski cells and HPV-39-positive ME180 cervical cancer cell lines respectively[1].PTP1B-IN-9 reduces the cell viability of exponentially growing HeLa cervical cancer cells in a dose-dependent fashion with an IC50 value of 2 µM[1]. Cell Viability Assay[1] Cell Line: Keratinocytes, SiHa, CaSki and ME180 cells

[1]. Anchoori RK, et al. Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells.PLoS One. 2011;6(8):e23888.